Clinical resource

Gynaecological cervix definitive brachytherapy boost (eviQ ID 1319)

eviQ, Cancer Institute NSW

View Source Source Verified

DoseLab summary

Endorsed eviQ protocol for the brachytherapy boost in definitive treatment of cervical cancer. It describes the insertion procedure (anesthesia, examination, Foley catheter, ultrasound-guided applicator placement, packing), CT or MRI planning with the GEC-ESTRO MRI sequences, the GTV, high-risk and intermediate-risk CTVs, the traditional ICRU 38 points, HDR schedules of 6–8 Gy in 3–5 fractions to the HR-CTV, and total EQD2 aims for the target and for bladder, rectum, sigmoid and bowel D2cc, most credited to EMBRACE II and GEC-ESTRO. Its review is due 31 December 2026.

Why this is useful

A practical cervix brachytherapy protocol: insertion procedure, CT/MRI simulation, GEC-ESTRO target volumes, ICRU 38 points and EQD2 aims for the HR-CTV and organs.

Reference details

Title
Gynaecological cervix definitive brachytherapy boost (eviQ ID 1319)
Authors / organization
eviQ, Cancer Institute NSW
Publication / protocol
eviQ Radiation Oncology protocol 1319
Version
v.5 — last reviewed 16 June 2022; review due 31 December 2026
Year
2022
DOI
Pending verification
Disease sites
GYN
Topics
Cervix, Brachytherapy, HDR, IGABT, EQD2, Dose Constraints, Protocols
Fractionation context
HR-CTV 24–30 Gy in 3–5 HDR fractions (6–8 Gy) after EBRT
Last reviewed by DoseLab
2026-09-30

Cited on DoseLab